Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies

Eur J Clin Invest 2012 Abstract Background Activin-A is a molecule of the TGF superfamily, implicated in liver fibrosis, regeneration and stem cell differentiation. However, data on activins in liver diseases are few. We therefore studied serum levels of activin-A in chronic liver diseases. To identify the origin of activin-A, levels in the hepatic vein were also estimated. Materials and methods Nineteen controls and 162 patients participated in the study: 39 with hepatocellular carcinoma (HCC: 19 viral associated and 20 alcohol associated), 18 with chronic hepatitis C (CHC), 47 with primary biliary cirrhosis (26 PBC stage III and 21 stage IV), 22 with alcoholic cirrhosis (AC, hepatic vein blood available in 16), 20 with HCV cirrhosis (hepatic vein blood available in 18) and 16 patients with alcoholic fatty liver with mild to moderate fibrosis but no cirrhosis. Results Activin-A levels were significantly increased (P < 0.001) in serum of patients with AC (median 673 pg/mL, range 4493279), compared with either controls (149 pg/mL, 91193) or patients with viral cirrhosis (189 pg/mL, 81480), CHC (142 pg/mL, 65559) PBC stage III (100 pg/mL, 59597) and PBC stage IV (104 pg/mL, 81579). Only patients with AC-associated HCC had significantly increased levels of activin-A (2403 pg/mL, 15617220 pg/mL). Activin-A serum levels could accurately discriminate AC from cirrhosis of other aetiologies and noncirrhotic alcoholic fatty liver with fibrosis. Conclusions Increased serum levels of activin-A only in patients with alcohol-related cirrhosis or HCC suggest a possible role of this molecule in the pathophysiology of AC. Further research is warranted to elucidate its role during the profibrotic process and its possible clinical applications.